Chief Financial Officer to leave Recipharm
Recipharm AB today announced that its Chief Financial Officer (CFO) Björn Westberg has resigned from his position with the company.
Thomas Eldered, CEO of Recipharm, said: “We are disappointed to be losing Mr Westberg and we would like to sincerely thank him for the significant contributions he has made to Recipharm in the past 10 years. He has been a strong leader and has brought invaluable expertise to the company.”
Mr Westberg will work out his contractual notice period and serve as CFO until the company’s full year report on February 23, 2017.
A search process has commenced to appoint a new CFO.
For further information please visit www.recipharm.com or contact:
Thomas Eldered, CEO, firstname.lastname@example.org , telephone: +46 8 602 52 10
This information is published in accordance with Chapter 4, Section 9 of the Swedish Financial Instruments Trading Act (SFS 1991:980).This information was submitted for publication on 19 December 2016, at 11:00 am CET.
Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 3,500 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 5.0 billion and the Company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com
Recipharm AB (publ)
Corporate identity number 556498-8425
Address Lagervägen 7, SE-136 50 Jordbro, Sweden, Telephone 46 8 602 52 00, Fax 46 8 81 87 03